Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

NCT01601704 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

8910

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight

Interventions

DRUG: NB32
DRUG: PBO
BEHAVIORAL: Weight Management Program

Sponsor

Orexigen Therapeutics, Inc